Themis receives FDA fast track designation for Chikungunya vaccine candidate27. February 2019|In Portfolio News|By eazee-designstudioThemis announced today that the US Food and Drug Administration (FDA) has granted fast track designation to the Company’s lead vaccine candidate (MV-CHIK) for the prevention of Chikungunya, a debilitating disease with global outbreak potential. The program is the most advanced Chikungunya vaccine candidate and has already successfully completed Phase 2 clinical development with results recently published in The Lancet. PrevNext
